EW
ITCI

Evoke Wealth’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Evoke Wealth’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-110
Closed -$5K – 1184
2022
Q3 		$5K Hold
110
– – ﹤0.01% 897
2022
Q2 		$6K Hold
110
– – ﹤0.01% 875
2022
Q1 		$7K Hold
110
– – ﹤0.01% 850
2021
Q4 		$6K Hold
110
– – ﹤0.01% 882
2021
Q3 		$4K Hold
110
– – ﹤0.01% 918
2021
Q2 		$4K Hold
110
– – ﹤0.01% 958
2021
Q1 		$4K Hold
110
– – ﹤0.01% 916
2020
Q4 		$3K Hold
110
– – ﹤0.01% 849
2020
Q3 		$3K Hold
110
– – ﹤0.01% 806
2020
Q2 		$3K Buy
+110
New +$2.23K ﹤0.01% 827

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Evoke Wealth's ITCI Position: Q4 2022 in Review

Evoke Wealth sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2022, closing a stake of 110 shares — an estimated $5K sold.

Evoke Wealth first reported a position in ITCI in Q2 2020 and held it in 10 quarters. The position peaked at $7K in Q1 2022. 283 funds tracked by Wall St. Rank hold ITCI as of Q4 2022.

  • Evoke Wealth reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2022 after selling out during the quarter.
  • Evoke Wealth sold 110 Intra-Cellular Therapies Inc. shares in Q4 2022, an estimated $5K.
  • Evoke Wealth first reported a position in Intra-Cellular Therapies Inc. in Q2 2020 and held it in 10 quarters.
  • Evoke Wealth's Intra-Cellular Therapies Inc. position peaked at $7K in Q1 2022.
  • 283 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2022.

Based on Evoke Wealth's 13F filing for Q4 2022, filed 10 Feb 2023.